Elliott PJ - Search Results

1

Proteasome inhibition: a new anti-inflammatory strategy.

Elliott PJ, Zollner TM, Boehncke WH. Elliott PJ, et al. J Mol Med (Berl). 2003 Apr;81(4):235-45. doi: 10.1007/s00109-003-0422-2. Epub 2003 Mar 26. J Mol Med (Berl). 2003. PMID: 12700891 Review.

2

Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.

Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Zollner TM, et al. Among authors: elliott pj. J Clin Invest. 2002 Mar;109(5):671-9. doi: 10.1172/JCI12736. J Clin Invest. 2002. PMID: 11877475 Free PMC article.

3

Assays for proteasome inhibition.

Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Elliott PJ, et al. Methods Mol Med. 2003;85:163-72. doi: 10.1385/1-59259-380-1:163. Methods Mol Med. 2003. PMID: 12710207 Review. No abstract available.

4

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. Cusack JC Jr, et al. Among authors: elliott pj. Cancer Res. 2001 May 1;61(9):3535-40. Cancer Res. 2001. PMID: 11325813

5

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP. Shah SA, et al. Among authors: elliott pj. J Cell Biochem. 2001 Apr 2-27;82(1):110-22. doi: 10.1002/jcb.1150. J Cell Biochem. 2001. PMID: 11400168

6

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. Hideshima T, et al. Among authors: elliott pj. Cancer Res. 2001 Apr 1;61(7):3071-6. Cancer Res. 2001. PMID: 11306489

7

Proteasome inhibition: a new strategy in cancer treatment.

Adams J, Palombella VJ, Elliott PJ. Adams J, et al. Among authors: elliott pj. Invest New Drugs. 2000 May;18(2):109-21. doi: 10.1023/a:1006321828515. Invest New Drugs. 2000. PMID: 10857991 Review.

8

The proteasome: a new target for novel drug therapies.

Elliott PJ, Ross JS. Elliott PJ, et al. Am J Clin Pathol. 2001 Nov;116(5):637-46. doi: 10.1309/44HW-5YCJ-FLLP-3R56. Am J Clin Pathol. 2001. PMID: 11710679 Review.

9

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ. Lazarus DD, et al. Among authors: elliott pj. Am J Physiol. 1999 Aug;277(2):E332-41. doi: 10.1152/ajpendo.1999.277.2.E332. Am J Physiol. 1999. PMID: 10444430

10

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Lightcap ES, et al. Among authors: elliott pj. Clin Chem. 2000 May;46(5):673-83. Clin Chem. 2000. PMID: 10794750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page